Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is in Phase 1 clinical trial and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics, Inc.

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Viridian Therapeutics today and set a price target of $35.00. Katkhuda covers the ...

Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tenaya Therapeutics (TNYA) and Viridian Therapeutics...

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Viridian Therapeutics, with a price target of $31.00. Archila...

Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)

What to make of the markets today? The biggest story in recent months has been the conflict in the Middle East and its effect on oil prices. After ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRDN	$23.59	+4.80%	1.66M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRDN	$23.59	+4.8%	1.66M
3
4
5
6

VRDN

VRDN

Get Viridian Therapeutics, Inc. Data in Excel

Get Viridian Therapeutics, Inc. Data in Excel